A 14-year retrospective review of angiosarcoma: Clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy Journal Article
| Authors: | Fury, M. G.; Antonescu, C. R.; Van Zee, K. J.; Brennan, M. F.; Maki, R. G. |
| Article Title: | A 14-year retrospective review of angiosarcoma: Clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy |
| Abstract: | PURPOSE: Angiosarcoma is a rare vascular malignancy, and there are few published data to guide chemotherapy treatment decisions. We present a retrospective analysis of angiosarcoma encompassing all anatomic sites of disease presenting to a single institution over a 14-year period. Characteristics at presentation and prognostic factors are reviewed. For patients with unresectable disease, progression-free survival with various chemotherapy regimens is described. PATIENTS AND METHODS: Pathological confirmation of all cases was performed before they were included in this analysis. One hundred twenty-five patients with angiosarcoma were seen and treated between January 1, 1990 and December 31, 2003. RESULTS: Angiosarcoma showed marked variation by anatomic site regarding gender ratio, median age at diagnosis, overall survival, and response to chemotherapy. Overall 5-year survival was 31% for angiosarcoma. Superficial depth and negative microscopic surgical margins correlated with longer overall survival, but tumor size did not reach significance as a prognostic factor. For unresectable angiosarcoma, doxorubicin-based regimens yielded progression-free survival of 3.7-5.4 months. Paclitaxel achieved a progression-free survival of 6.8 months for scalp angiosarcoma and 2.8 months for sites below the clavicle. DISCUSSION: Angiosarcoma is an aggressive malignancy characterized by biologic heterogeneity at different anatomic sites and relative sensitivity to paclitaxel and doxorubicin. Copyright © 2005 Jones and Bartlett Publishers, Inc. |
| Keywords: | adult; controlled study; treatment outcome; treatment response; aged; aged, 80 and over; disease-free survival; middle aged; retrospective studies; major clinical study; overall survival; clinical feature; disease course; histopathology; review; cancer localization; cancer recurrence; doxorubicin; fluorouracil; gemcitabine; paclitaxel; disease free survival; methotrexate; temozolomide; cancer staging; follow up; antineoplastic agent; neoplasm staging; demography; carboplatin; dacarbazine; metastasis; tumor volume; antineoplastic combined chemotherapy protocols; antineoplastic agents, phytogenic; pathology; angiosarcoma; hemangiosarcoma; retrospective study; ifosfamide; vinblastine; docetaxel; disease progression; sex difference; mesna; sex factors; navelbine; antibiotics, antineoplastic; drug dose regimen; antineoplastic antibiotic; onset age; age of onset; surgical anatomy; retrospective; edatrexate; tecogalan; abdominal angiosarcoma; breast angiosarcoma; extremity angiosarcoma; head and neck angiosarcoma; pelvis angiosarcoma; scalp angiosarcoma; thorax angiosarcoma |
| Journal Title: | The Cancer Journal |
| Volume: | 11 |
| Issue: | 3 |
| ISSN: | 1528-9117 |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2005-05-01 |
| Start Page: | 241 |
| End Page: | 247 |
| Language: | English |
| DOI: | 10.1097/00130404-200505000-00011 |
| PUBMED: | 16053668 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 63" - "Export Date: 24 October 2012" - "CODEN: CAJOC" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work